BiotechTube
NovaLead Pharma

NovaLead Pharma

Cambridge, United States· Est.
novaleadpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

NovaLead Pharma is a private, venture-backed biotech founded in 2016, leveraging a proprietary in-silico drug repositioning platform to discover new therapeutic uses for generic drugs. Its most advanced program, Galnobax® for Diabetic Foot Ulcer, has met primary and secondary endpoints in Phase III, leading to a recent out-licensing deal with Ipca Laboratories for the Indian market. The company's pipeline includes additional candidates like NLP91 for psoriasis, targeting a combined addressable market estimated at over $10 billion annually. NovaLead's model is to out-license discoveries after proof-of-concept, minimizing late-stage safety risks.

Diabetic Foot UlcerPsoriasisChronic WoundsInflammatory Skin Diseases

Technology Platform

Proprietary in-silico Reverse Virtual High Throughput Screening (RVHTS) platform for identifying new biological targets and indications for generic drugs.

Funding History

1
Total raised:$15M
Series A$15M

Opportunities

The successful Phase III results for Galnobax® create a significant opportunity to out-license the asset in major global markets beyond India, such as the US and EU, where the DFU burden is high.
The growing diabetic population worldwide expands the addressable patient base for Galnobax® annually.
Furthermore, validating and advancing the NLP91 program for psoriasis could tap into a large, chronic market with demand for new therapeutic options.

Risk Factors

The company's success is heavily reliant on securing licensing partners for development and commercialization, particularly in high-value markets.
While safety is de-risked, efficacy in broader populations and regulatory acceptance for new indications are not guaranteed.
Competition in both the DFU and psoriasis spaces is intense, with numerous companies developing novel therapies.

Competitive Landscape

In DFU, NovaLead's Galnobax® competes with advanced wound care products (e.g., Smith & Nephew, 3M), growth factor therapies, and other emerging drug candidates. Its differentiation lies in being a repurposed drug with a known safety profile and a novel mechanism to restart healing. In psoriasis, NLP91 would enter a crowded market dominated by biologics and small molecules, competing on potential cost, safety, and oral/topical administration advantages.

More companies in Small Molecule Drugs →More companies in United States →